Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1997 May;41(5):977–981. doi: 10.1128/aac.41.5.977

Topotecan inhibits human immunodeficiency virus type 1 infection through a topoisomerase-independent mechanism in a cell line with altered topoisomerase I.

J L Zhang 1, P L Sharma 1, C J Li 1, B J Dezube 1, A B Pardee 1, C S Crumpacker 1
PMCID: PMC163836  PMID: 9145855

Abstract

Topotecan (TPT), a known inhibitor of topoisomerase I, has previously been shown to inhibit the replication of several viruses. The mechanism of inhibition was proposed to be the inhibition of topoisomerase I. We report that TPT decreased replication of human immunodeficiency virus type 1 (HIV-1) in CPT-K5, a cell line with a topoisomerase I mutation. TPT inhibited production of HIV-1 RNA and p24 in CPT-K5 and wild-type cells equally effectively. The antiviral effects of TPT were observed not only in the topoisomerase-mutated CPT-K5 line but also in peripheral blood mononuclear cells (PBMC) acutely infected with clinical isolates and in OM10.1 cells latently infected with HIV and activated by tumor necrosis factor alpha. Little toxicity from TPT was noted in HIV-1-infected PBMC and in CPT-K5 and OM10.1 cells as measured by cell growth and proliferation assays. These observations suggest that TPT targets factors in virus replication other than cellular topoisomerase I and inhibits cytokine-mediated activation in latently infected cells by means other than cytotoxicity. These results suggest a potential for TPT and for other camptothecins in anti-HIV therapy alone and in combination with other antiretroviral drugs.

Full Text

The Full Text of this article is available as a PDF (313.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andoh T., Ishii K., Suzuki Y., Ikegami Y., Kusunoki Y., Takemoto Y., Okada K. Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I. Proc Natl Acad Sci U S A. 1987 Aug;84(16):5565–5569. doi: 10.1073/pnas.84.16.5565. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bendixen C., Thomsen B., Alsner J., Westergaard O. Camptothecin-stabilized topoisomerase I-DNA adducts cause premature termination of transcription. Biochemistry. 1990 Jun 12;29(23):5613–5619. doi: 10.1021/bi00475a028. [DOI] [PubMed] [Google Scholar]
  3. Butera S. T., Perez V. L., Wu B. Y., Nabel G. J., Folks T. M. Oscillation of the human immunodeficiency virus surface receptor is regulated by the state of viral activation in a CD4+ cell model of chronic infection. J Virol. 1991 Sep;65(9):4645–4653. doi: 10.1128/jvi.65.9.4645-4653.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Chen A. Y., Yu C., Potmesil M., Wall M. E., Wani M. C., Liu L. F. Camptothecin overcomes MDR1-mediated resistance in human KB carcinoma cells. Cancer Res. 1991 Nov 15;51(22):6039–6044. [PubMed] [Google Scholar]
  5. Chou T. C., Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984;22:27–55. doi: 10.1016/0065-2571(84)90007-4. [DOI] [PubMed] [Google Scholar]
  6. Covey J. M., Jaxel C., Kohn K. W., Pommier Y. Protein-linked DNA strand breaks induced in mammalian cells by camptothecin, an inhibitor of topoisomerase I. Cancer Res. 1989 Sep 15;49(18):5016–5022. [PubMed] [Google Scholar]
  7. Hendricks C. B., Rowinsky E. K., Grochow L. B., Donehower R. C., Kaufmann S. H. Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue. Cancer Res. 1992 Apr 15;52(8):2268–2278. [PubMed] [Google Scholar]
  8. Hertzberg R. P., Caranfa M. J., Hecht S. M. On the mechanism of topoisomerase I inhibition by camptothecin: evidence for binding to an enzyme-DNA complex. Biochemistry. 1989 May 30;28(11):4629–4638. doi: 10.1021/bi00437a018. [DOI] [PubMed] [Google Scholar]
  9. Hsiang Y. H., Hertzberg R., Hecht S., Liu L. F. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem. 1985 Nov 25;260(27):14873–14878. [PubMed] [Google Scholar]
  10. Hsiang Y. H., Liu L. F. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res. 1988 Apr 1;48(7):1722–1726. [PubMed] [Google Scholar]
  11. Hsiang Y. H., Liu L. F., Wall M. E., Wani M. C., Nicholas A. W., Manikumar G., Kirschenbaum S., Silber R., Potmesil M. DNA topoisomerase I-mediated DNA cleavage and cytotoxicity of camptothecin analogues. Cancer Res. 1989 Aug 15;49(16):4385–4389. [PubMed] [Google Scholar]
  12. Jaxel C., Capranico G., Kerrigan D., Kohn K. W., Pommier Y. Effect of local DNA sequence on topoisomerase I cleavage in the presence or absence of camptothecin. J Biol Chem. 1991 Oct 25;266(30):20418–20423. [PubMed] [Google Scholar]
  13. Kaufmann W. K., Boyer J. C., Estabrooks L. L., Wilson S. J. Inhibition of replicon initiation in human cells following stabilization of topoisomerase-DNA cleavable complexes. Mol Cell Biol. 1991 Jul;11(7):3711–3718. doi: 10.1128/mcb.11.7.3711. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Larder B. A., Kemp S. D. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science. 1989 Dec 1;246(4934):1155–1158. doi: 10.1126/science.2479983. [DOI] [PubMed] [Google Scholar]
  15. Leonard J., Parrott C., Buckler-White A. J., Turner W., Ross E. K., Martin M. A., Rabson A. B. The NF-kappa B binding sites in the human immunodeficiency virus type 1 long terminal repeat are not required for virus infectivity. J Virol. 1989 Nov;63(11):4919–4924. doi: 10.1128/jvi.63.11.4919-4924.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Li C. J., Zhang L. J., Dezube B. J., Crumpacker C. S., Pardee A. B. Three inhibitors of type 1 human immunodeficiency virus long terminal repeat-directed gene expression and virus replication. Proc Natl Acad Sci U S A. 1993 Mar 1;90(5):1839–1842. doi: 10.1073/pnas.90.5.1839. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Mattern M. R., Hofmann G. A., McCabe F. L., Johnson R. K. Synergistic cell killing by ionizing radiation and topoisomerase I inhibitor topotecan (SK&F 104864). Cancer Res. 1991 Nov 1;51(21):5813–5816. [PubMed] [Google Scholar]
  18. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983 Dec 16;65(1-2):55–63. doi: 10.1016/0022-1759(83)90303-4. [DOI] [PubMed] [Google Scholar]
  19. Priel E., Showalter S. D., Blair D. G. Inhibition of human immunodeficiency virus (HIV-1) replication in vitro by noncytotoxic doses of camptothecin, a topoisomerase I inhibitor. AIDS Res Hum Retroviruses. 1991 Jan;7(1):65–72. doi: 10.1089/aid.1991.7.65. [DOI] [PubMed] [Google Scholar]
  20. Priel E., Showalter S. D., Roberts M., Oroszlan S., Blair D. G. The topoisomerase I inhibitor, camptothecin, inhibits equine infectious anemia virus replication in chronically infected CF2Th cells. J Virol. 1991 Aug;65(8):4137–4141. doi: 10.1128/jvi.65.8.4137-4141.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Rowinsky E. K., Grochow L. B., Hendricks C. B., Ettinger D. S., Forastiere A. A., Hurowitz L. A., McGuire W. P., Sartorius S. E., Lubejko B. G., Kaufmann S. H. Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor. J Clin Oncol. 1992 Apr;10(4):647–656. doi: 10.1200/JCO.1992.10.4.647. [DOI] [PubMed] [Google Scholar]
  22. Shin C. G., Snapka R. M. Patterns of strongly protein-associated simian virus 40 DNA replication intermediates resulting from exposures to specific topoisomerase poisons. Biochemistry. 1990 Dec 11;29(49):10934–10939. doi: 10.1021/bi00501a011. [DOI] [PubMed] [Google Scholar]
  23. Slichenmyer W. J., Von Hoff D. D. New natural products in cancer chemotherapy. J Clin Pharmacol. 1990 Sep;30(9):770–788. doi: 10.1002/j.1552-4604.1990.tb01873.x. [DOI] [PubMed] [Google Scholar]
  24. Takahashi H., Matsuda M., Kojima A., Sata T., Andoh T., Kurata T., Nagashima K., Hall W. W. Human immunodeficiency virus type 1 reverse transcriptase: enhancement of activity by interaction with cellular topoisomerase I. Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5694–5698. doi: 10.1073/pnas.92.12.5694. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Tamura H., Kohchi C., Yamada R., Ikeda T., Koiwai O., Patterson E., Keene J. D., Okada K., Kjeldsen E., Nishikawa K. Molecular cloning of a cDNA of a camptothecin-resistant human DNA topoisomerase I and identification of mutation sites. Nucleic Acids Res. 1991 Jan 11;19(1):69–75. doi: 10.1093/nar/19.1.69. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Yamada Y., Yamamoto N., Maeno K., Nishiyama Y. Role of DNA topoisomerase I in the replication of herpes simplex virus type 2. Arch Virol. 1990;110(1-2):121–127. doi: 10.1007/BF01310708. [DOI] [PubMed] [Google Scholar]
  27. Zhang L., Waters C., Nichols J., Crumpacker C. Inhibition of HIV-1 RNA production by the diphtheria toxin-related IL-2 fusion proteins DAB486IL-2 and DAB389IL-2. J Acquir Immune Defic Syndr. 1992 Dec;5(12):1181–1187. [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES